In this issue:
Prevalence of cardiovascular events
Cost-effectiveness of axi-cel versus tisa-cel
SPMs post CAR-T
Kinetics of cytopenia
Onset and duration of ICANS and CRS
Current CAR-T cell management in EBMT
PROs and risk factors for worse QoL and toxicities
Efficacy of risk-based approaches
ASCT post CAR-T cell therapy
COVID-19 effects pre- and post-infusion
Please login below to download this issue (PDF)